In patients with colorectal cancer, EGFR therapy-resistant KRAS mutant subclones support non-mutant therapy-sensitive cells by secreting increased levels of TGFalpha and amphiregulin [79], in turn sustaining EGFR/ERK signalling in sensitive cells [79]. The gene discussed is KRAS; the disease is colorectal cancer.